Early Reconstruction with Locoregional-Free Flaps in Post-COVID-19 Rhino-orbital-cerebral Mucormycosis Craniofacial Deformities: A Single-Center Clinical Experience from India

 

 Permissions and Reprints

Abstract

Aim of the Study Mucormycosis is a rare invasive and fatal fungal infection and its resurgence in coronavirus disease 2019 (COVID-19) patients has been a matter of grave concern. It is essentially a medical disease, but surgical debridement of necrotic tissues is of paramount importance leading to severe craniofacial deformities. In this case series, we present our experience with the feasibility of early reconstruction after surgical debridement.

Case Series As a Dedicated COVID Center (DCH), the institute received the largest population of COVID-19 mucormycosis patients from the entire eastern region of the country between May 2021 and August 2021. More than 5,000 COVID-19 were admitted out of which 218 patients were diagnosed with mucormycosis. Nine patients, seven males and two females, with a mean age of 39 years with craniofacial mucormycosis underwent debridement and early reconstructions (2–4 weeks from first debridement and start of antifungal therapy) with free and pedicled flaps. All flaps survived and showed no evidence of recurrence. The average time of the early reconstruction after surgical debridement was 1.7 weeks once the course of systemic amphotericin B was received.

Conclusion After aggressive surgical resection and a short course of antifungal therapy, early reconstruction can be done safely based on clinical criteria, as long as there is no evidence of hyphae invasion on wound edges in the intraoperative pathology examination.

Publication History

Received: 16 August 2023

Accepted: 13 December 2023

Article published online:
15 January 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 2020; 26 (10) 1395-1399
  CrossrefPubMedGoogle Scholar
• 2 Ripa M, Galli L, Poli A. et al; COVID-BioB study group. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect 2021; 27 (03) 451-457
  CrossrefPubMedGoogle Scholar
• 3 Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020; 185 (04) 599-606
  CrossrefPubMedGoogle Scholar
• 4 Arastehfar A, Carvalho A, van de Veerdonk FL. et al. COVID-19 associated pulmonary aspergillosis (CAPA) – from immunology to treatment. J Fungi (Basel) 2020; 6 (02) 91
  CrossrefPubMedGoogle Scholar
• 5 Salehi M, Ahmadikia K, Badali H, Khodavaisy S. Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. Mycopathologia 2020; 185 (04) 607-611
  CrossrefPubMedGoogle Scholar
• 6 Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug resistant Candida auris infections in critically ill coronavirus disease patients. Emerg Infect Dis 2020; 26 (11) 2694-2696
  CrossrefPubMedGoogle Scholar
• 7 Scheckenbach K, Cornely O, Hoffmann TK. et al. Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. Auris Nasus Larynx 2010; 37 (03) 322-328
  CrossrefPubMedGoogle Scholar
• 8 Vairaktaris E, Moschos MM, Vassiliou S. et al. Orbital cellulitis, orbital subperiosteal and intraorbital abscess: report of three cases and review of the literature. J Craniomaxillofac Surg 2009; 37 (03) 132-136
  CrossrefPubMedGoogle Scholar
• 9 Gillespie MB, O'Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am 2000; 33 (02) 323-334
  CrossrefPubMedGoogle Scholar
• 10 Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17 (06) 517-525
  CrossrefPubMedGoogle Scholar
• 11 Elinav H, Zimhony O, Cohen MJ, Marcovich AL, Benenson S. Rhinocerebral mucormycosis in patients without predisposing medical conditions: a review of the literature. Clin Microbiol Infect 2009; 15 (07) 693-697
  CrossrefPubMedGoogle Scholar
• 12 Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6 (10) 2365-2374
  CrossrefPubMedGoogle Scholar
• 13 Auluck A. Maxillary necrosis by mucormycosis. a case report and literature review. Med Oral Patol Oral Cir Bucal 2007; 12 (05) E360-E364
  PubMedGoogle Scholar
• 14 Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15 (04) 102146
  CrossrefPubMedGoogle Scholar
• 15 Torroni A, Romano F, Longo G, Lombardo G. Reconstruction of mid-facial defect secondary to rhinomaxillary mucormycosis: report of a challenging case and literature review. Clin Res Infect Dis 2015; 2 (02) 1020
  PubMedGoogle Scholar
• 16 Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (1, suppl 1): S23-S34
  CrossrefPubMedGoogle Scholar
• 17 Groote CA. Rhinocerebral phycomycosis. Arch Otolaryngol 1970; 92 (03) 288-292
  CrossrefPubMedGoogle Scholar
• 18 Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18 (03) 556-569
  CrossrefPubMedGoogle Scholar
• 19 Kumari A, Rao NP, Patnaik U. et al. Management outcomes of mucormycosis in COVID-19 patients: a preliminary report from a tertiary care hospital. Med J Armed Forces India 2021; 77 (Suppl. 02) S289-S295
  CrossrefPubMedGoogle Scholar
• 20 Roden MM, Zaoutis TE, Buchanan WL. et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41 (05) 634-653
  CrossrefPubMedGoogle Scholar
• 21 Silberstein E, Krieger Y, Rosenberg N. et al. Facial reconstruction of a mucormycosis survivor by free rectus abdominis muscle flap, tissue expansion, and ocular prosthesis. Ophthal Plast Reconstr Surg 2016; 32 (06) e131-e132
  CrossrefPubMedGoogle Scholar
• 22 Augustine HFM, White C, Bain J. Aggressive combined medical and surgical management of mucormycosis results in disease eradication in 2 pediatric patients. Plast Surg (Oakv) 2017; 25 (03) 211-217
  CrossrefPubMedGoogle Scholar
• 23 Lari AR, Kanjoor JR, Vulvoda M, Katchy KC, Khan ZU. Orbital reconstruction following sino-nasal mucormycosis. Br J Plast Surg 2002; 55 (01) 72-75
  CrossrefPubMedGoogle Scholar
• 24 Bhatnagar A, Agarwal A. Naso-orbital fistula and socket reconstruction with radial artery forearm flap following orbital mucormycosis. Natl J Maxillofac Surg 2016; 7 (02) 197-200
  CrossrefPubMedGoogle Scholar
• 25 Odessey E, Cohn A, Beaman K, Schechter L. Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation. Surg Infect (Larchmt) 2008; 9 (01) 91-98
  CrossrefPubMedGoogle Scholar
• 26 Adler N, Seitz IA, Gottlieb LJ. Acute wound closure and reconstruction following head zygomycosis: presentation of two cases and review of literature. J Reconstr Microsurg 2008; 24 (07) 507-513
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Tidwell J, Higuera S, Hollier Jr LH. Facial reconstruction after mucormycosis in an immunocompetent host. Am J Otolaryngol 2005; 26 (05) 333-336
  CrossrefPubMedGoogle Scholar